Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Federal Reserve shifts to quarter-point rate rise but warns of more to come
    • Battle of Bakhmut nears tipping point as Russia intensifies offensive
    • Stocks and bonds soar as investors bet that rates are close to peak
    • Military briefing: does Ukraine need western fighter jets?
    • Economists detect dovish undertones from ‘more optimistic’ Jay Powell
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Gautam Adani defends ‘robust’ business as stock losses reach $100bn
      • New York property tycoon to give worn-out offices ‘back to the bank’
      • Jo Johnson quits as director of UK firm with Adani ties
      • Adani Enterprises calls off $2.4bn share sale
      • Goldman to fund meagre payouts to banks hammered by Archegos collapse
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Adani Enterprises calls off $2.4bn share sale
      • Live news: US labour market shows resilience even as business investment ticks down
      • Shell profits more than double to record $40bn
      • US stocks jump after Fed announces smaller rate rise
      • Live news updates from February 1: Fed lifts rates 0.25 points, Eurozone inflation slows sharply
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
      Most Read
      • The return of the ‘British disease’
      • Beware the great battery industry fallacy
      • End the Fed ‘put’
      • OK boomer, you’re more generous than we thought
      • Conservatives are forced to face the economic case for net zero
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • A new generation refuses to keep quiet on age discrimination at work
      • Shoshana Zuboff: ‘Privacy has been extinguished. It is now a zombie’
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Retiring at 62? The French have it absolutely right
      • Alexa Chung on the unpolished appeal of Indie Sleaze
      • Why I’m only buying five new things in 2023
      • Amy Hwang’s cartoons about life and work
      • Annie Morris and Idris Khan’s guide to West Sussex
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Dementia

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Wednesday, 11 January, 2023
      Anjana Ahuja
      New Alzheimer’s drug straddles uneasy gulf between help and harm

      For all its landmark status, lecanemab may end up representing a triumph of hope over evidence

    • Thursday, 29 December, 2022
      Biogen Inc
      Congress faults US regulator’s approval of Biogen Alzheimer’s drug

      Committees cite inappropriate collaboration between FDA and drugmaker

    • Friday, 2 December, 2022
      Pharmaceuticals sector
      Swedish scientist behind Alzheimer’s drug has big ambitions

      Lars Lannfelt had a key role in developing a drug that has shown some promise in tackling Alzheimer’s

    • Friday, 2 December, 2022
      The editorial board
      A glimmer of hope in treating Alzheimer’s disease

      Dementia drug development, diagnostics and delivery still require much more investment

    • Wednesday, 30 November, 2022
      Eisai says Alzheimer’s drug did not cause deaths of trial patients

      Japanese company refuses to rule out possibility treatment contributed to brain bleeds

    • Tuesday, 29 November, 2022
      Eisai Co Ltd
      Japan’s Eisai aims to silence critics over breakthrough Alzheimer’s drug

      Shares fall 11% following two patient deaths in trials of lecanemab

    • Monday, 28 November, 2022
      LexDrugs research
      Dementia/Biogen: causal controversy means investors must take a stance Premium content

      The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down

    • Monday, 14 November, 2022
      Roche Holding AG
      Roche late-stage Alzheimer’s trials end in failure

      Two studies of antibody treatment gantenerumab fail to slow decline in people with early-stage disease

    • Sunday, 13 November, 2022
      Insurance
      AI is giving insurers godlike powers, says Sompo chief

      Access to large data sets means predictions are far more accurate in reducing risk

    • Monday, 24 October, 2022
      Special ReportFT Health: Communicable Diseases
      Evidence builds of viruses’ role in Alzheimer’s disease

      Researchers focus on pathogens including Covid, herpes and Epstein-Barr virus

    • Wednesday, 28 September, 2022
      Pharmaceuticals sector
      Biogen and Eisai shares surge after Alzheimer’s drug trial success

      Pharma groups seek US regulatory approval as clinical trial shows monoclonal antibody treatment slowed disease

    • Friday, 23 September, 2022
      Health sector
      Alzheimer’s drug trial brings pivotal test of maligned brain plaque theory

      Study of Eisai treatment will be one of last chances to prove amyloid hypothesis, say experts

    • Monday, 22 August, 2022
      Medical science
      Electrical brain stimulation improves memory in elderly, research finds

      Study could be used to help boost cognitive performance of people developing Alzheimer’s disease

    • Wednesday, 17 August, 2022
      Coronavirus pandemic
      Covid can cause brain disorders two years after infection, study shows

      Long-term effects are generally less in children, although infection doubles risk of epilepsy

    • Wednesday, 18 May, 2022
      Coronavirus pandemic
      How can Covid-19 affect the human brain?

      Scientists are trying to understand the cause of neurological effects and whether symptoms will be long-lasting

    • Sunday, 17 April, 2022
      Anjana Ahuja
      Hasty approval for Alzheimer’s drug offers a cautionary tale

      FDA’s green light for aducanumab may delay development of more effective treatments for dementia, critics say

    • Friday, 8 April, 2022
      News in-depthPharmaceuticals sector
      US imposes strict curbs on contentious Biogen Alzheimer’s treatment

      Agency that controls spending by government health schemes will not fund drug for most patients

    • Thursday, 13 January, 2022
      ReviewNon-Fiction
      What I Wish People Knew About Dementia — uplifting depiction

      Practical and reassuring tale written with eloquence and insight about a disease which for years was presumed to rob sufferers of sentience

    • Wednesday, 20 October, 2021
      Biogen Inc
      Biogen sells just $300,000 worth of contentious Alzheimer’s drug

      Third-quarter revenues from $56,000-per-year treatment were well below analysts’ expectation of $10m

    • Wednesday, 1 September, 2021
      Scientists warn that Covid will accelerate ‘dementia pandemic’

      Experts point to mounting evidence that the virus can cause long-term brain damage in some patients

    • Thursday, 22 July, 2021
      Biogen Inc
      Biogen defends contentious $56,000 Alzheimer’s drug

      Pharma group blames ‘misinformation’ for overshadowing approval of therapy

    • Sunday, 18 July, 2021
      Coronavirus treatment
      UK to study causes, diagnosis and treatment of long Covid

      Research to focus on future health burden as variants and looser restrictions drive up cases

    • Friday, 9 July, 2021
      US Food & Drug Administration
      FDA calls for probe of staff involved in divisive Alzheimer’s approval

      US drugs watchdog was under pressure after scientific outcry over controversial Biogen treatment

    • Monday, 5 July, 2021
      News in-depthPharmaceuticals sector
      Approval of Biogen Alzheimer’s drug reignites ‘amyloid’ debate

      Hypothesis that brain plaques cause disease viewed with scepticism by some scientists

    • Wednesday, 16 June, 2021
      Pharmaceuticals sector
      Biogen’s Japanese partner calls for global action on Alzheimer’s

      Eisai says framework for testing and treatment urgently needed in response to ‘secret pandemic’

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In